Drugs that contain Pasireotide Pamoate
1. List of Signifor Lar Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(4 months from now) | |
| US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(3 years from now) | |
| US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 29, 2025 |
Market Authorisation Date: 15 December, 2014
Treatment: Method of treating acromegaly
Dosage: FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT family patents
11
United States
8
European Union
5
Korea, Republic of
4
Australia
4
Norway
3
Israel
3
South Africa
3
Denmark
3
Mexico
3
Slovenia
3
Argentina
3
Brazil
3
Portugal
3
Malaysia
3
Spain
3
Peru
3
Poland
3
Taiwan, Province of China
3
China
3
Ecuador
3
United Kingdom
3
Japan
3
Canada
3
New Zealand
2
Austria
2
Hong Kong
2
Russia
2
Morocco
2
Hungary
2
Germany
2
Cyprus
2
Luxembourg
2
Tunisia
1
El Salvador
1
Slovakia
1
Belgium
1
Uruguay
1
Cuba
1
Costa Rica
1
Colombia
1
Honduras
1
Croatia
1
Guatemala
1
Dominican Republic
1
Czech Republic
1
San Marino
1
Iceland
1
Chile
1
Nicaragua
1
Ukraine
1
Georgia
1
EA
1
Panama
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic